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Abstract
A blood cell lineage consists of several consecutive developmental stages from
the pluripotent or multipotent stem cell to a particular stage of terminally dif-
ferentiated cells. There is considerable interest in identifying the key regulatory
genes that govern blood cell development from the gene expression data with-
out considering the underlying network between transcription factors (TFs) and
their target genes. In this study, we introduce a novel expression pattern that
key regulators expose along the differentiation path. We deploy this pattern
to identify the cell-specific key regulators responsible for the development. As
proof of concept, we consider this approach to data on six developmental stages
from mouse embryonic stem cells to terminally differentiated macrophages.
1 Introduction
The problem of identification of key player genes in gene regulatory networks
(GRNs) mainly addressing cell cycle process has been explained in our previous
study [1]. In that study, we considered the set of genes that form the minimum
dominating set (MDS) and minimum connected dominating set (MCDS) in the
largest connected component of the underlying network as the key player genes.
In this study, we focus on the identification of key regulatory genes driving blood
cell development based on the pattern of gene expression data that they expose
for particular stage along the cell development. We got inspired by the pattern
of gene expression of the global regulators where the set of global regulators
introduced in [2]. In that study, a dynamic core regulatory network is presented
by multi-omics analysis where the network consists of 16 TFs that drive cellular
differentiation from ESC to terminally differentiated macrophages. Embryonic
stem cells (ESCs), Mesoderm (MES), Hemangioblast (HB), Hemogenic endothe-
lium (HE), Hematopoietic progenitor (HP) and Macrophages (MAC) constitute
the six consecutive developmental stages. These global regulators which have
separate representations for all the developmental stages are connected to each
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other through a dense network. The network is inferred through a deep muli-
omics analysis by generating data for RNA-seq, ChIP-seq and DNA-seq mea-
suring global gene expression, chromatin accessibility, histone modifications and
transcription factor binding data. Although this network is preserved across all
the developmental stages, but the global regulators have separate representa-
tions in each stage, e.g, Nanog, Esrrb, Pou5f1 and Sox2 are highly expressed in
embryonic stem cell (ESC), where their expression level reach to the least level in
the macrophages with gradual decrease along the path. Plotting the expression
level of global regulators for all six stages of development with respect to the
highest expressed regulators in particular cells inspired us to identify the cell-
specific key regulators driving blood cell development from the gene expression
data, see Figure 1. The main idea is that a key player associated with a certain
differentiated cell has the highest expression value in that cell among all the cells
in the lineage. Therefore, the key genes associated with an undifferentiated cell
at the top of the lineage have the highest expression level initially, however, the
expression level decreases gradually. This pattern of expression looks different
for the key players of the cells in the middle stages. In the middle stages, the
expression value of a key player gene starts with the least expression value at the
top of the hierarchy with a gradual increase along the differentiation path that
reaches to the maximum value in the target cell and then decreases gradually
till it reaches to the terminally differentiated cells. The genes with the highest
expression values at the terminally differentiated cells among all the cells with
the gradual increase in expression level from the initial stage are considered as
candidates for the key players in those cells.
2 Results
We applied our supervised method to data on six developmental stages from
ESCs to terminally differentiated macrophages compiled by (Goode et al. 2016)
[2]. The key players in the ESCs have the highest expression level at the initial
stage. The expression level decreases gradually when it reaches to the terminally
differentiated cells. For other cells along the lineage, the related genes have the
least expression value at the ESCs and the highest in the target cells with a
gradual decrease till it reaches to the final stage, see Figure 2. This approach
identified 332 genes including 22 TFs based on the above-mentioned expression
pattern in the ESC stage including Sox2 and Esrrb. Pou5f1 has almost the
similar pattern such that it has the highest expression value at the ESC stage,
gradually decreases till HE, then less than one unit increase in HP and again
reduction till MAC (ESC: 382.02500, MES: 219.5270000, HB: 47.8558000, HE:
0.687413, HP: 1.19097, MAC: 0.000000). For Nanog the exception occurred at
stage HE such that the expression value at HE is slightly less than HP and MAC
(ESC: 58.0737, MES: 34.6255, HB: 5.18978, HE: 0.055367, HP: 0.0734063,
MAC: 0.0159039). Similarly, 18 TFs were identified for MES and 57, 29, 21 and
10 for HB, HE, HP and MAC among 332, 702, 506, 201 and 309 genes. The set
of TFs were extracted from TF-gene interaction database [3].
2.1 Functional annotation
In this work, the biological function of the genes in each stage was evaluated
using the enrichment analysis tool provided at the DAVID portal of NIH (version
6.8) based on the functional categories in GO Direct [4]. p-values below the
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Figure 1: Expression of the global regulators driving hematopoietic specification for
all six stages of blood development from ESCs.
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Figure 2: Depiction of the set of TFs for 6 stages of development following the pattern
of expression.
threshold 0.05 obtained by the hypergeometric test were adjusted for multiple
testing using the Benjamini & Hochberg (BH) method [5].
2.2 Enrichment analysis fo the set of identified TFs
Enrichment analysis for the set of identified TFs in the ESC stage yielded the
enriched biological process GO terms and KEGG pathways listed in Table S1.
The list includes GO terms such as GO:0048863, GO:0007275, GO:0007492 and
GO:0030154 annotated to stem cell differentiation, multicellular organism devel-
opment, endoderm development and cell differentiation, respectively. Moreover,
the set of genes (Onecut1, Esrrb, Id1, Sox2, Zic3) are related to the KEGG
pathway: mmu04550 annotated to signaling pathways regulating pluripotency
of stem cells. Tables S2-S6 list the enriched GO terms and KEGG pathways
for the identified TFs in MES, HB, HE, HP and MAC. The lists include new
specialized GO terms in addition to some of the aforementioned terms such as
GO:0001569, GO:0045165, GO:0007507 and GO:0030097 annotated to pattern-
ing of blood vessels, cell fate commitment, heart development and hemopoiesis,
respectively and also a KEGG pathway: mmu05221 annotated to acute myeloid
leukemia.
2.3 Enrichment analysis for the set of identified tar-
get genes
We inferred the set of target genes for the set of identified TFs from TF-gene
interaction database TRRUST [3]. Enrichment analysis for the set of identified
target genes in the ESC stage yielded the enriched biological process GO terms
and KEGG pathways listed in Table S7. The list includes GO terms such as
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GO:0042127, GO:0007275, GO:0048863, GO:0030154, GO:0045165, GO:0048468
and GO:0008283 annotated to regulation of cell proliferation, multicellular or-
ganism development, stem cell differentiation, cell differentiation, cell fate com-
mitment, cell development and cell proliferation, respectively. Tables S8-S12
list the enriched GO terms for the target genes in other developmental stages.
In addition to common GO terms, distinct GO terms such as GO:0061312 and
GO:0016055 with annotations BMP signaling pathway involved in heart devel-
opment and Wnt signaling pathway are added in MES stage. More specialized
GO terms appear in later stages HB and HE and HP such as GO:0001889,
GO:0002326, GO:0043583 and GO:0001654 with annotations liver development,
B cell lineage commitment, ear development and eye development, respectively.
2.4 Prioritization of the identified TFs
Although the identified TFs in each particular developmental stage follow the
aforementioned expression pattern, but they expose different expression levels.
Histograms in Figure 3 show the frequency of TFs based on expression level. As
the expression level increases, the number of associated TFs reduces.
Figure 3: Histograms of cell-specific TFs in the blood cell lineage.
To prioritize the set of identified TFs, we considered a statistical measure
such as quantile. We used 5-quantiles that divides the set of genes into 5 equal
groups, see Figure 4. For each cut point, the set of identified genes were consid-
ered that are greater or equal the quantile value. Figure 5 shows the number of
TFs among the genes. The plots in figure 5 show all the identified TFs initially
with constant decrease while increasing the quantile value.
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Figure 4: Number of stage-specific genes based on different quantiles.
Figure 5: Number of stage-specific TFs based on different quantiles.
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3 Conclusion
We proposed an expression pattern for the identification of biomarkers driv-
ing blood cell development. This expression pattern helps to infer the patient-
specific biomarkers by considering just the expression level across the cell lineage.
No prior knowledge of the regulatory interaction between genes is required to
derive the set of biomarkers. We have prioritized the set of identified cell-specific
TFs and genes based on the expression pattern. Enrichment analysis suggests
that these biomarkers can be potential targets for disease-related biomarkers
such as leukaemia.
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